Scholarlink

<p>Multidrug-resistant pathogens are an increasing problem in cardiac, thoracic and vascular surgery. Immunosuppressed patients and infections associated with implants are particularly affected as the risk of implant removal is often too high. As antibiotic treatment is losing effectiveness, the World Health Organization (WHO) calls for innovative treatment strategies. A&#xa0;promising alternative is phage treatment, which selectively lyses bacterial pathogens. Initial clinical reports indicate good efficacy and tolerability, especially for antibiotic-resistant infections. In western countries, phage treatment is still used off-label and requires individual case decisions. While already established in Belgium and France, its development in Germany is still in the developmental phase. Despite regulatory hurdles, research on phage safety, efficacy and production is increasing. This article provides an overview of the current status of phage treatment in Germany, its clinical evidence in cardiac and vascular surgery and potential recommendations for the clinical implementation.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bakteriophagentherapie bei kritischen Infektionen in der Herz‑, Thorax- und Gefäßchirurgie

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月6日

查看全文
  • Evgenii Rubalskii,
  • Stefan Rümke,
  • Axel Haverich,
  • Arjang Ruhparwar,
  • Christian Kühn

摘要

Multidrug-resistant pathogens are an increasing problem in cardiac, thoracic and vascular surgery. Immunosuppressed patients and infections associated with implants are particularly affected as the risk of implant removal is often too high. As antibiotic treatment is losing effectiveness, the World Health Organization (WHO) calls for innovative treatment strategies. A promising alternative is phage treatment, which selectively lyses bacterial pathogens. Initial clinical reports indicate good efficacy and tolerability, especially for antibiotic-resistant infections. In western countries, phage treatment is still used off-label and requires individual case decisions. While already established in Belgium and France, its development in Germany is still in the developmental phase. Despite regulatory hurdles, research on phage safety, efficacy and production is increasing. This article provides an overview of the current status of phage treatment in Germany, its clinical evidence in cardiac and vascular surgery and potential recommendations for the clinical implementation.